CRF 2 receptors are highly expressed in the human cardiovascular system and their cognate ligands urocortins 2 and 3 are potent vasodilators
Systemic infusions of urocortin 1 produce a decrease in mean arterial pressure. This effect may be mediated by a direct action on novel corticotropin‐releasing factor type 2 (CRF 2 ) receptors predicted to be expressed in blood vessels and the heart. Our objectives were to determine the presence of...
Saved in:
Published in | British journal of pharmacology Vol. 143; no. 4; pp. 508 - 514 |
---|---|
Main Authors | , |
Format | Journal Article |
Language | English |
Published |
17.02.2009
|
Online Access | Get full text |
Cover
Loading…
Abstract | Systemic infusions of urocortin 1 produce a decrease in mean arterial pressure. This effect may be mediated by a direct action on novel corticotropin‐releasing factor type 2 (CRF
2
) receptors predicted to be expressed in blood vessels and the heart. Our objectives were to determine the presence of CRF
2
receptors in the human cardiovascular system using the selective radioligand [
125
I]antisauvagine 30. We also investigated the potential functional roles of novel CRF
2
ligands in the regulation of vascular tone in human arteries
in vitro
.
Radioligand binding techniques were used to characterise the CRF
2
receptor. [
125
I]antisauvagine 30 bound specifically, saturably, reversibly and with high affinity to CRF
2
receptors in human left ventricle (
K
D
0.21±0.03 n
M
,
B
MAX
0.80±0.18 fmol mg
−1
protein), and no change in receptor density or affinity was observed in the dilated cardiomyopathy group.
Autoradiographical studies revealed highly localised binding of [
125
I]antisauvagine 30 to intramyocardial blood vessels. Binding sites were also detected in the myocardium and in the medial layer of internal mammary arteries.
In endothelium‐denuded human internal mammary artery
in vitro
, all peptides tested produced a potent and sustained vasodilator response reversing endothelin‐1‐induced constrictions (10 n
M
) (urocortin 1: p
D
2
8.39±0.32,
E
MAX
46±7.7%; urocortin 2: p
D
2
8.27±0.17,
E
MAX
60±8.5%; urocortin 3: p
D
2
8.61±0.25,
E
MAX
61±7.2%; CRF: p
D
2
8.28±0.27,
E
MAX
: 40±10%).
We have demonstrated the presence of CRF
2
receptors in the human cardiovascular system and a direct, endothelium‐independent vasodilator action of urocortins 2 and 3, which may counter‐balance the centrally mediated pressor effects of CRF and urocortin 1.
British Journal of Pharmacology
(2004)
143
, 508–514. doi:
10.1038/sj.bjp.0705985 |
---|---|
AbstractList | Systemic infusions of urocortin 1 produce a decrease in mean arterial pressure. This effect may be mediated by a direct action on novel corticotropin‐releasing factor type 2 (CRF
2
) receptors predicted to be expressed in blood vessels and the heart. Our objectives were to determine the presence of CRF
2
receptors in the human cardiovascular system using the selective radioligand [
125
I]antisauvagine 30. We also investigated the potential functional roles of novel CRF
2
ligands in the regulation of vascular tone in human arteries
in vitro
.
Radioligand binding techniques were used to characterise the CRF
2
receptor. [
125
I]antisauvagine 30 bound specifically, saturably, reversibly and with high affinity to CRF
2
receptors in human left ventricle (
K
D
0.21±0.03 n
M
,
B
MAX
0.80±0.18 fmol mg
−1
protein), and no change in receptor density or affinity was observed in the dilated cardiomyopathy group.
Autoradiographical studies revealed highly localised binding of [
125
I]antisauvagine 30 to intramyocardial blood vessels. Binding sites were also detected in the myocardium and in the medial layer of internal mammary arteries.
In endothelium‐denuded human internal mammary artery
in vitro
, all peptides tested produced a potent and sustained vasodilator response reversing endothelin‐1‐induced constrictions (10 n
M
) (urocortin 1: p
D
2
8.39±0.32,
E
MAX
46±7.7%; urocortin 2: p
D
2
8.27±0.17,
E
MAX
60±8.5%; urocortin 3: p
D
2
8.61±0.25,
E
MAX
61±7.2%; CRF: p
D
2
8.28±0.27,
E
MAX
: 40±10%).
We have demonstrated the presence of CRF
2
receptors in the human cardiovascular system and a direct, endothelium‐independent vasodilator action of urocortins 2 and 3, which may counter‐balance the centrally mediated pressor effects of CRF and urocortin 1.
British Journal of Pharmacology
(2004)
143
, 508–514. doi:
10.1038/sj.bjp.0705985 |
Author | Davenport, Anthony P Wiley, Katherine E |
Author_xml | – sequence: 1 givenname: Katherine E surname: Wiley fullname: Wiley, Katherine E – sequence: 2 givenname: Anthony P surname: Davenport fullname: Davenport, Anthony P |
BookMark | eNotkF1LwzAUhoNMcJveep0_0JqPpk0vZTgVBoLodUnT0y2lS0qSifsP_mhT3dWB97wf8KzQwjoLCN1TklPC5UMY8naYclIRUUtxhZa0qMpMcEkXaEkIqTJKpbxBqxAGQtKzEkv0s3nfYoY9aJii8wErD_hg9ofxjOF78hACdNhYHA9JPx2VxVr5zrgvFfRpVB6Hc4hwxMp2s8d4rN3eqgh4NPskBnzyTjsfjQ1paLbxv5HJRbARpx7XmVHN47fouldjgLvLXaPP7dPH5iXbvT2_bh53maaCxUxqxgpetorxoit5rTQIUFxXJS9ETQSrJNVtqdiMQgit2r6CntE6RXohGV-j_L9XexeCh76ZvDkqf24oaWaWTRiaxLK5sOS_pLtsow |
CitedBy_id | crossref_primary_10_1016_j_ijcard_2015_06_011 crossref_primary_10_1016_j_jacc_2006_09_035 crossref_primary_10_1111_j_1440_1681_2010_05466_x crossref_primary_10_1016_j_peptides_2022_170748 crossref_primary_10_1097_FJC_0000000000000190 crossref_primary_10_1371_journal_pone_0217065 crossref_primary_10_1089_hum_2014_157 crossref_primary_10_1111_j_1476_5381_2012_01904_x crossref_primary_10_1152_ajpheart_00377_2007 crossref_primary_10_1016_j_cpcardiol_2021_100860 crossref_primary_10_1016_j_molmet_2022_101492 crossref_primary_10_1016_j_ijcard_2007_11_026 crossref_primary_10_1007_s00380_011_0141_5 crossref_primary_10_1016_j_neulet_2017_05_012 crossref_primary_10_1177_1074248420985301 crossref_primary_10_1155_2012_395284 crossref_primary_10_1161_CIRCHEARTFAILURE_112_000205 crossref_primary_10_1042_CS20070364 crossref_primary_10_1161_HYPERTENSIONAHA_111_173203 crossref_primary_10_1093_cvr_cvp161 crossref_primary_10_1016_j_drudis_2018_09_004 crossref_primary_10_1021_jm0613875 crossref_primary_10_1210_en_2006_0565 crossref_primary_10_1096_fj_05_5315fje crossref_primary_10_1161_HYPERTENSIONAHA_108_125211 crossref_primary_10_1042_BJ20090311 crossref_primary_10_1016_j_fertnstert_2006_05_041 crossref_primary_10_1161_CIRCHEARTFAILURE_108_840207 crossref_primary_10_1210_en_2009_1454 crossref_primary_10_1016_j_bcp_2010_03_032 crossref_primary_10_1152_ajpheart_00391_2010 crossref_primary_10_1161_CIRCULATIONAHA_105_561308 crossref_primary_10_1016_j_aqrep_2024_102110 crossref_primary_10_1016_j_jpsychires_2010_04_020 crossref_primary_10_1161_JAHA_112_004267 crossref_primary_10_1016_j_yfrne_2006_09_002 crossref_primary_10_1111_bcp_13033 crossref_primary_10_1093_cvr_cvq063 crossref_primary_10_1097_HJH_0b013e3283493776 crossref_primary_10_1210_er_2005_0034 crossref_primary_10_1016_j_yjmcc_2015_07_023 crossref_primary_10_1152_ajpheart_00353_2013 crossref_primary_10_1016_j_ajog_2005_12_048 crossref_primary_10_1097_FJC_0b013e31822707a4 crossref_primary_10_1007_s10557_019_06895_9 crossref_primary_10_1016_j_ejphar_2007_09_018 crossref_primary_10_1248_bpb_30_985 crossref_primary_10_1097_CRD_0b013e31827ed0c9 crossref_primary_10_1161_01_RES_0000219904_43852_3e crossref_primary_10_1002_med_21268 crossref_primary_10_1007_s00125_022_05675_9 crossref_primary_10_1016_j_cca_2017_09_003 crossref_primary_10_1210_en_2007_0678 crossref_primary_10_1093_cvr_cvy076 crossref_primary_10_2217_fca_10_13 crossref_primary_10_1042_CS20050079 crossref_primary_10_1016_j_abb_2018_11_021 crossref_primary_10_1016_j_vph_2023_107275 crossref_primary_10_1002_cne_24307 crossref_primary_10_1073_pnas_0712366105 crossref_primary_10_1161_CIRCHEARTFAILURE_109_861336 crossref_primary_10_1016_S1734_1140_09_70019_2 crossref_primary_10_3109_10715762_2010_485988 crossref_primary_10_1042_CS20120468 crossref_primary_10_1016_j_peptides_2006_07_005 crossref_primary_10_1089_hum_2013_088 crossref_primary_10_1097_XCE_0000000000000024 crossref_primary_10_1016_j_jacbts_2017_12_004 crossref_primary_10_1152_ajpheart_00694_2013 |
Cites_doi | 10.1038/sj.bjp.0704815 10.1073/pnas.051626398 10.1007/BF00606625 10.1038/87936 10.1210/jc.84.8.2802 10.1172/JCI112204 10.1016/S0014-2999(03)01725-4 10.1042/CS20030311 10.1016/0002-9149(91)90511-I 10.1111/j.1476-5381.1993.tb13490.x 10.1161/01.CIR.98.17.1735 10.1210/endo.137.5.8612563 10.1677/joe.0.1690177 10.1097/00005344-200310000-00015 10.1073/pnas.121165198 10.1016/S0028-3908(00)00105-2 10.1038/sj.bjp.0704670 10.1016/S0196-9781(98)00175-2 10.1016/S0167-4781(97)00047-X 10.1038/sj.bjp.0702182 10.1161/01.CIR.0000028424.02525.AE 10.1152/ajpheart.2000.279.6.H3031 10.1016/S0167-0115(03)00003-X 10.1126/science.6267699 10.1210/jcem.87.1.8160 10.1038/74255 10.1124/pr.55.1.3 10.1152/ajpheart.1997.272.5.H2115 10.1016/0167-0115(83)90123-4 10.1038/sj.bjp.0704587 10.1161/01.CIR.81.3.741 10.1038/sj.bjp.0703939 10.1038/sj.bjp.0703834 10.1016/0006-2952(96)00300-0 10.1038/sj.bjp.0704228 10.1056/NEJM199110033251404 |
ContentType | Journal Article |
DBID | AAYXX CITATION |
DOI | 10.1038/sj.bjp.0705985 |
DatabaseName | CrossRef |
DatabaseTitle | CrossRef |
DatabaseTitleList | CrossRef |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Pharmacy, Therapeutics, & Pharmacology |
EISSN | 1476-5381 |
EndPage | 514 |
ExternalDocumentID | 10_1038_sj_bjp_0705985 |
GroupedDBID | --- .3N 05W 0R~ 1OC 23N 24P 2WC 33P 36B 3O- 3SF 4.4 52U 52V 53G 5GY 6J9 8-0 8-1 8UM A00 AAESR AAEVG AAHHS AANLZ AAONW AASGY AAXRX AAYXX AAZKR ABCUV ABDBF ABPVW ABQWH ABXGK ACAHQ ACCFJ ACCZN ACFBH ACGFO ACGFS ACGOF ACMXC ACPOU ACPRK ACXBN ACXQS ADBBV ADBTR ADEOM ADIZJ ADKYN ADMGS ADOZA ADXAS ADZMN ADZOD AEEZP AEGXH AEIGN AEIMD AENEX AEQDE AEUQT AEUYR AFBPY AFFPM AFGKR AFPWT AFRAH AFZJQ AHBTC AHMBA AIACR AIAGR AITYG AIURR AIWBW AJBDE ALAGY ALIPV ALMA_UNASSIGNED_HOLDINGS ALUQN AMBMR AMYDB AOIJS ATUGU AZBYB AZVAB B0M BAFTC BAWUL BFHJK BHBCM BMXJE BRXPI C45 CAG CITATION COF CS3 DCZOG DIK DRFUL DRMAN DRSTM DU5 E3Z EAD EAP EAS EBC EBD EBS ECV EJD EMB EMK EMOBN ENC ESX F5P FUBAC G-S GODZA GX1 H.X HGLYW HYE HZ~ KBYEO LATKE LEEKS LH4 LITHE LOXES LSO LUTES LW6 LYRES MEWTI MK0 MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM MY~ N9A NF~ O66 O9- OIG OK1 OVD P2P P2W P4E Q.N QB0 RIG ROL RPM RWI SJN SUPJJ SV3 TEORI TR2 TUS UPT WBKPD WH7 WHWMO WIH WIJ WIK WIN WOHZO WVDHM WXSBR XV2 YHG ZGI ZZTAW ~8M ~S- |
ID | FETCH-LOGICAL-c152t-8c22436ba234d639ace5ea3c763459052781cb6a2070555cabf7ef2196baf5823 |
ISSN | 0007-1188 |
IngestDate | Fri Aug 23 00:35:48 EDT 2024 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 4 |
Language | English |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c152t-8c22436ba234d639ace5ea3c763459052781cb6a2070555cabf7ef2196baf5823 |
PageCount | 7 |
ParticipantIDs | crossref_primary_10_1038_sj_bjp_0705985 |
PublicationCentury | 2000 |
PublicationDate | 2009-02-17 |
PublicationDateYYYYMMDD | 2009-02-17 |
PublicationDate_xml | – month: 02 year: 2009 text: 2009-02-17 day: 17 |
PublicationDecade | 2000 |
PublicationTitle | British journal of pharmacology |
PublicationYear | 2009 |
References | e_1_2_7_5_1 KIMURA Y. (e_1_2_7_19_1) 2002; 87 e_1_2_7_4_1 e_1_2_7_9_1 e_1_2_7_8_1 e_1_2_7_7_1 e_1_2_7_18_1 e_1_2_7_17_1 e_1_2_7_16_1 e_1_2_7_40_1 e_1_2_7_2_1 e_1_2_7_41_1 e_1_2_7_14_1 e_1_2_7_13_1 e_1_2_7_12_1 e_1_2_7_11_1 e_1_2_7_10_1 DAVENPORT A.P. (e_1_2_7_6_1) 2002; 206 e_1_2_7_26_1 e_1_2_7_27_1 e_1_2_7_28_1 e_1_2_7_29_1 JAIN V. (e_1_2_7_15_1) 1999; 288 CLARKE J.G. (e_1_2_7_3_1) 1989; 257 e_1_2_7_30_1 e_1_2_7_25_1 e_1_2_7_31_1 e_1_2_7_24_1 e_1_2_7_32_1 e_1_2_7_23_1 e_1_2_7_33_1 e_1_2_7_22_1 e_1_2_7_34_1 e_1_2_7_21_1 e_1_2_7_35_1 e_1_2_7_36_1 e_1_2_7_37_1 e_1_2_7_38_1 e_1_2_7_39_1 KUC R.E. (e_1_2_7_20_1) 2002; 206 |
References_xml | – ident: e_1_2_7_40_1 doi: 10.1038/sj.bjp.0704815 – ident: e_1_2_7_29_1 doi: 10.1073/pnas.051626398 – ident: e_1_2_7_10_1 doi: 10.1007/BF00606625 – ident: e_1_2_7_13_1 doi: 10.1038/87936 – ident: e_1_2_7_33_1 doi: 10.1210/jc.84.8.2802 – ident: e_1_2_7_34_1 doi: 10.1172/JCI112204 – ident: e_1_2_7_25_1 doi: 10.1016/S0014-2999(03)01725-4 – ident: e_1_2_7_26_1 doi: 10.1042/CS20030311 – ident: e_1_2_7_12_1 doi: 10.1016/0002-9149(91)90511-I – ident: e_1_2_7_22_1 doi: 10.1111/j.1476-5381.1993.tb13490.x – ident: e_1_2_7_41_1 doi: 10.1161/01.CIR.98.17.1735 – ident: e_1_2_7_7_1 doi: 10.1210/endo.137.5.8612563 – ident: e_1_2_7_35_1 doi: 10.1677/joe.0.1690177 – ident: e_1_2_7_16_1 doi: 10.1097/00005344-200310000-00015 – ident: e_1_2_7_24_1 doi: 10.1073/pnas.121165198 – ident: e_1_2_7_11_1 doi: 10.1016/S0028-3908(00)00105-2 – ident: e_1_2_7_31_1 doi: 10.1038/sj.bjp.0704670 – volume: 257 start-page: H2033 year: 1989 ident: e_1_2_7_3_1 article-title: Endothelin is a potent long‐lasting vasoconstrictor in men publication-title: Am. J. Physiol. contributor: fullname: CLARKE J.G. – ident: e_1_2_7_38_1 doi: 10.1016/S0196-9781(98)00175-2 – ident: e_1_2_7_36_1 doi: 10.1016/S0167-4781(97)00047-X – ident: e_1_2_7_32_1 doi: 10.1038/sj.bjp.0702182 – ident: e_1_2_7_21_1 doi: 10.1161/01.CIR.0000028424.02525.AE – ident: e_1_2_7_27_1 doi: 10.1152/ajpheart.2000.279.6.H3031 – ident: e_1_2_7_2_1 doi: 10.1016/S0167-0115(03)00003-X – volume: 206 start-page: 45 year: 2002 ident: e_1_2_7_20_1 article-title: Radioligand binding assays and quantitative autoradiography of endothelin receptors publication-title: Methods Mol. Biol. contributor: fullname: KUC R.E. – ident: e_1_2_7_37_1 doi: 10.1126/science.6267699 – volume: 87 start-page: 340 year: 2002 ident: e_1_2_7_19_1 article-title: Expression of urocortin and corticotropin‐releasing factor receptor subtypes in the human heart publication-title: J. Clin. Endocrinol. Metab. doi: 10.1210/jcem.87.1.8160 contributor: fullname: KIMURA Y. – ident: e_1_2_7_4_1 doi: 10.1038/74255 – ident: e_1_2_7_9_1 doi: 10.1124/pr.55.1.3 – ident: e_1_2_7_28_1 doi: 10.1152/ajpheart.1997.272.5.H2115 – ident: e_1_2_7_8_1 doi: 10.1016/0167-0115(83)90123-4 – ident: e_1_2_7_14_1 doi: 10.1038/sj.bjp.0704587 – ident: e_1_2_7_5_1 doi: 10.1161/01.CIR.81.3.741 – ident: e_1_2_7_17_1 doi: 10.1038/sj.bjp.0703939 – ident: e_1_2_7_39_1 doi: 10.1038/sj.bjp.0703834 – volume: 288 start-page: 407 year: 1999 ident: e_1_2_7_15_1 article-title: Endothelium‐dependent and ‐independent mechanisms of vasorelaxation by corticotropin‐releasing factor in pregnant rat uterine artery publication-title: J. Pharmacol. Exp. Ther. contributor: fullname: JAIN V. – ident: e_1_2_7_30_1 doi: 10.1016/0006-2952(96)00300-0 – volume: 206 start-page: 45 year: 2002 ident: e_1_2_7_6_1 article-title: Radioligand binding assays and quantitative autoradiography of endothelin receptors publication-title: Methods Mol. Biol. contributor: fullname: DAVENPORT A.P. – ident: e_1_2_7_18_1 doi: 10.1038/sj.bjp.0704228 – ident: e_1_2_7_23_1 doi: 10.1056/NEJM199110033251404 |
SSID | ssj0014775 |
Score | 2.2825289 |
Snippet | Systemic infusions of urocortin 1 produce a decrease in mean arterial pressure. This effect may be mediated by a direct action on novel corticotropin‐releasing... |
SourceID | crossref |
SourceType | Aggregation Database |
StartPage | 508 |
Title | CRF 2 receptors are highly expressed in the human cardiovascular system and their cognate ligands urocortins 2 and 3 are potent vasodilators |
Volume | 143 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwELaWcuGCeArKQ3NA5ZBmSWI7To6oUBUqUIW2Um9RYjsoq9Xuqskeym_oP-ifZRw7L-ihcIlWkR0rmW_nYc98Q8i7smBaUWb6u-DfDbVf7CcsTP1QhWEZCqlEbuqdv32PT87Z1wt-MZvdjLKWdk0xl79urSv5H6niPZSrqZL9B8n2D8Ub-Bvli1eUMF7vJOOjH8de5KHO0tu2aY7J4jL8w6srw9zf0oKrLpHRNuOT0_RTy-PcZVFWl57JJkLv01tVP00NsLdD-7YxRAM1LmSG0XaR7aYxOQT4nI2qViZuryenw44paURLsR0osodN_MptmJ92ZYjemP1gaHPvGA5cLVq3R5GatGZbktnrXeFjKGM1rbaqlonYR3UbTnSx5WxyoGMjzcqDZGSkua08_Uv_W7b3ejkvlts5ajOe2oZAU6LtPwxgn5bYHsjTJKuXGc7P3Px75H4kUm4i-09fTvsjKiaEbY_hXq1jBKXJh-n6I49n5LosHpGHLuaAjxZAj8lMr5-QgzMrkatDWAw1ePUhHMDZSFZPyTWiDCLoUQYIALAogx5lUK0BZQgtymCKMrAoA4QPtCgDhzJwKIMBZbiQGUbbRSzKYIyyZ-T8-PPi6MR3PTx8iZ5h4ycSfUQaF3lEmUJvOJea65xKNGuMpwGPRBLKIs4j87E4l3lRCl2iGcUpJU8i-pzsrTdr_YIA2nQWJEqLPJIMw6w0obFSpQq4NgXawUvyvvvO2dZStWS3S3T_ziNfkQcDnl-TveZyp9-gF9oUb1s0_AYVfI7_ |
link.rule.ids | 315,786,790,27957,27958 |
linkProvider | Flying Publisher |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=CRF+2+receptors+are+highly+expressed+in+the+human+cardiovascular+system+and+their+cognate+ligands+urocortins+2+and+3+are+potent+vasodilators&rft.jtitle=British+journal+of+pharmacology&rft.au=Wiley%2C+Katherine+E&rft.au=Davenport%2C+Anthony+P&rft.date=2009-02-17&rft.issn=0007-1188&rft.eissn=1476-5381&rft.volume=143&rft.issue=4&rft.spage=508&rft.epage=514&rft_id=info:doi/10.1038%2Fsj.bjp.0705985&rft.externalDBID=n%2Fa&rft.externalDocID=10_1038_sj_bjp_0705985 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0007-1188&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0007-1188&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0007-1188&client=summon |